A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes
3 other identifiers
interventional
400
1 country
40
Brief Summary
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started May 2026
40 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 11, 2026
CompletedFirst Posted
Study publicly available on registry
May 15, 2026
CompletedStudy Start
First participant enrolled
May 15, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 1, 2028
June 24, 2026
June 1, 2026
1.3 years
May 11, 2026
June 19, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Percent Change from Baseline in Body Weight
Baseline, Week 36
Secondary Outcomes (5)
Percent Change from Baseline in Body Weight
Baseline, Week 48
Change from Baseline in Body Weight
Baseline, Week 36
Percentage of Participants who Achieve ≥5% Body Weight Reduction
Week 36
Percentage of Participants who Achieve ≥10% Body Weight Reduction
Week 36
Change from Baseline in Body Mass Index (BMI)
Baseline, Week 36
Study Arms (8)
Macupatide Dose 1
EXPERIMENTALParticipants will receive macupatide subcutaneously (SC)
Eloralintide Dose 1
EXPERIMENTALParticipants will receive eloralintide SC
Macupatide Dose 1 + Eloralintide Dose 1
EXPERIMENTALParticipants will receive macupatide SC and eloralintide SC
Eloralintide Dose 2
EXPERIMENTALParticipants will receive eloralintide SC
Macupatide Dose 1 + Eloralintide Dose 2
EXPERIMENTALParticipants will receive macupatide SC and eloralintide SC
Eloralintide Dose 3
EXPERIMENTALParticipants will receive eloralintide SC
Macupatide Dose 2 + Eloralintide Dose 3
EXPERIMENTALParticipants will receive macupatide SC and eloralintide SC
Placebo
PLACEBO COMPARATORParticipants will receive placebo SC
Interventions
Administered SC
Administered SC
Eligibility Criteria
You may not qualify if:
- Have type 1 diabetes or type 2 diabetes
- Have an ongoing history of bradyarrhythmia and/or sinus bradycardia
- Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm)
- Have a history of acute or chronic pancreatitis
- All concomitant medications should be at a stable dose for at least 3 months prior to screening
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (40)
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
Chandler, Arizona, 85225, United States
Headlands Research - Scottsdale
Scottsdale, Arizona, 85260, United States
The Institute for Liver Health II dba Arizona Liver Health-Tucson
Tucson, Arizona, 85712, United States
NorCal Medical Research, Inc
Greenbrae, California, 94904, United States
Velocity Clinical Research, Huntington Park
Huntington Park, California, 90255, United States
Peninsula Research Associates
Rolling Hills Estates, California, 90274, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, 94598, United States
Stamford Therapeutics Consortium
Stamford, Connecticut, 06905, United States
New Horizon Research Center
Miami, Florida, 33165, United States
Indago Research & Health Center, Inc
Miami Lakes, Florida, 33016, United States
Suncoast Clinical Research, Inc.
New Port Richey, Florida, 34652, United States
Charter Research - Winter Park
Orlando, Florida, 32803, United States
Charter Research - Lady Lake
The Villages, Florida, 32162, United States
Medical Research Partners
Ammon, Idaho, 83406, United States
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois, 60640, United States
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas, 66606, United States
Monroe Biomedical Research - Louisville
Louisville, Kentucky, 40213, United States
Knownwell
Needham, Massachusetts, 02492, United States
Lucida Clinical Trials
New Bedford, Massachusetts, 02740, United States
Headlands Research - Detroit
Southfield, Michigan, 48034, United States
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan, 48098, United States
StudyMetrix Research
City of Saint Peters, Missouri, 63303, United States
Clinvest Headlands Llc
Springfield, Missouri, 65807, United States
Las Vegas Medical Research
Las Vegas, Nevada, 89128, United States
Dent Neurologic Institute
Amherst, New York, 14226, United States
Rochester Clinical Research, LLC
Rochester, New York, 14609, United States
Medication Management
Greensboro, North Carolina, 27405, United States
Monroe Biomedical Research
Monroe, North Carolina, 28112, United States
Lucas Research, Inc
Morehead City, North Carolina, 28557, United States
Lucas Research, Inc.
New Bern, North Carolina, 28562, United States
CTI Clinical Research Center
Cincinnati, Ohio, 45212, United States
Tribe Clinical Research, LLC
Greenville, South Carolina, 29607, United States
Quality Medical Research
Nashville, Tennessee, 37211, United States
IMA Clinical Research Austin
Austin, Texas, 78745, United States
FutureSearch Trials of Dallas
Dallas, Texas, 75251, United States
PlanIt Research, PLLC
Houston, Texas, 77079, United States
Endeavor Clinical Trials
San Antonio, Texas, 78240, United States
Texas Valley Clinical Research
Weslaco, Texas, 78596, United States
Sovah Clinical Research-River District
Danville, Virginia, 24541, United States
Central Washington Health Services Association d/b/a Confluence Health
Wenatchee, Washington, 98801, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
Central Study Contacts
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
Physicians interested in becoming principal investigators please contact
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 11, 2026
First Posted
May 15, 2026
Study Start
May 15, 2026
Primary Completion (Estimated)
September 1, 2027
Study Completion (Estimated)
February 1, 2028
Last Updated
June 24, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
- Access Criteria
- A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.